Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991-2000

Clinical Infectious Diseases

Volumn 37, Issue 12, 2003, Pages 1643-1648

  Zervos, Marcus J ^a,b   Hershberger, Ellie ^a,b   Nicolau, David P ^c   Ritchie, David J ^d,e   Blackner, Lori K ^f   Coyle, Elizabeth A ^g,h   Donnelly, Andrew J ^i,j   Eckel, Stephen F ^k   Eng, Robert H K ^l   Hiltz, Alexandra ⁿ   Kuyumjian, Arpi G ^m   Krebs, William ^o   McDaniel, Angee ^p   Hogan, Patricia ^p   Lubowski, Teresa J ^p  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

^e ST LOUIS COLLEGE OF PHARMACY   (United States)

^f Erlanger Medical Center   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF HOUSTON   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^k UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF COLORADO HOSPITAL   (United States)

^o Independent Statistical Consultant   (United States)

^p PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CITROBACTER; DRUG USE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TEACHING HOSPITAL; UNITED STATES;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; FLUOROQUINOLONES; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 10744220364     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379709     Document Type: Article

References (21)

1. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24(Suppl 1):S67-73.
2. Ena J, del Mar López-Perezagua M, Martínez-Peinado C, de los Angeles Cia-Barrio M, Ruíz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998; 30:103-7.
3. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-9.
4. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999; 29:245-52.
5. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999; 43(Suppl A):31-40.
6. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
7. Saurina G, Quale JM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45:895-8.
8. Chan-Tack KM. Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999. South Med J 2001; 94:619-20.
9. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404-21.
10. Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32:162-6.
11. Fridkin SK, Hill HA, Volkova NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg Infect Dis 2002; 8:697-701.
12. Livermore DM, James D, Reacher M, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8:473-8.
13. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002; 35:1505-11.
14. US Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. Document no. OTA-H-629. Washington, DC: US Government Printing Office, 1995.
15. McGowan JE Jr. Antimicrobial resistances in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033-48.
16. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11:757-65.
17. Friedrich LV, White RL, Bosso JA. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infect Dis 1999; 28:1017-24.
18. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46:2540-5.
19. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
20. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-70.
21. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1-9.